Leslie S. Kean

This study identifies CD8-iTreg as potent anti-tumor effectors and GVHD suppressors through Granzyme-K+ supramolecular attack particles.

This study edits Cyclophilin A's C-terminus using CRISPR/Cas9 to create cell therapies resistant to cyclosporine and voclosporin, preserving function in immune suppression settings.

This study compares the effects of two GVHD prophylaxis regimens on the gut microbiome in allo-HCT recipients and finds that while PTCy reduces microbiome diversity and bile acid metabolism, it is linked to better clinical outcomes.

The paper identifies a novel mechanism where CAR-T cell therapy activates CD8+ cytotoxic bystander T cells in non-human primates and patients, showing they can kill leukemic cells independently of TCR.

The paper profiles interneurons in primates and rodents to identify evolutionary innovations in brain cell types and their molecular features.